Michel, et al.. HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation.
Biallelic inactivating mutations of the transcription factor 1 gene (TCF1), encoding hepatocyte nuclear factor 1α (HNF1α), were identified in 50% of hepatocellular adenomas (HCA) phenotypically characterized by a striking steatosis. To understand the molecular basis of this aberrant lipid storage, we performed a microarray transcriptome analysis validated by quantitative RT-PCR, western-blotting and lipid profiling. In mutated HCA, we showed a repression of gluconeogenesis coordinated with an activation of glycolysis, citrate shuttle and fatty acid synthesis predicting elevated rates of lipogenesis. Moreover, the strong dowregulation of L-FABP suggests that impaired fatty acid trafficking may also contribute to the fatty phenotype. In addition, transcriptional profile analysis of the observed deregulated genes in non-HNF1αmutated HCA as well as in non-tumor livers allowed us to define a specific signature of the HNF1α-mutated HCA. In theses tumors, lipid composition was dramatically modified according to the transcriptional deregulations identified in the fatty acid synthetic pathway. Surprisingly, lipogenesis activation did not operate through SREBP-1 and ChREBP that were repressed. We conclude that steatosis in HNF1α-mutated HCA results mainly from an aberrant promotion of lipogenesis that is linked to HNF1α inactivation and that is independent of both SREBP-1 and ChREBP activation. Finally, our findings have potential clinical implications since lipogenesis can be efficiently inhibited by targeted therapies.
Hepatocyte nuclear factor 1-α (HNF1α) is a transcription factor that controls the expression of liver-specific genes, such as βfibrinogen, α1-antitrypsin and albumin (1) . Heterozygous germline mutations in the gene encoding HNF1α (TCF1) are responsible for an autosomal dominant form of non-insulindependent diabetes mellitus called maturity onset diabetes of the young type 3 (MODY3), in which subjects usually develop hyperglycemia before 25 years of age (2) . More recently, we identified HNF1α as a tumor suppressor gene involved in human liver tumorigenesis, since we found biallelic inactivating mutations of this gene in 50% of hepatocellular adenomas (HCA) and in rare cases of well-differentiated hepatocellular carcinomas developed in the absence of cirrhosis (3) . HCA are rare benign primary liver tumors closely related to oral contraceptive intake (4) .
Recently, in a comprehensive analysis of genotype-phenotype correlations in a large series of 96 HCA, we showed that HNF1α mutations define an homogeneous group of tumors phenotypically characterized by the recurrent presence of a marked steatosis (5) . To get insight into the underlying molecular mechanisms that drive the fatty phenotype in human HNF1α-HNF1α inactivation promotes hepatic lipogenesis mutated HCA, we performed a transcriptome analysis using cDNA and Affymetrix microarrays. Gene expression profiles were compared between non-tumor livers and HNF1α-mutated HCA. Among the differentially expressed genes we focused our analysis on genes involved in lipid homeostasis and we searched for a possible alteration in fat transport, degradation and synthesis processes. Transcriptomic deregulations were further validated in an additional series of tumors, but also at the protein level and we analyzed the precise composition of accumulated lipids.
EXPERIMENTAL PROCEDURES
Patients and samples. A series of 40 HCA, 25 non steatotic non-tumor livers and 11 steatotic non-tumor livers were collected in 9 French surgery departments from 1992 to 2004. Liver tissues were immediately frozen in liquid nitrogen and stored at -80°C until used for molecular studies. Among the 38 patients with an HCA, the sex ratio (M:F) was 1:9 and the mean age was 37 (median=37 years ranging from 14 to 56). All the patients were recruited in accordance with French law and institutional ethical guidelines. The study was approved by the ethical committee of Hôpital Saint-Louis, Paris, France. All HCA were screened for HNF1α and ß-catenin mutation, pathological slides were reviewed and all HCA were classified as previously described (5) . Twenty five HCA from 23 patients were HNF1αmutated, 11 demonstrated steatosis in more than 2/3 of hepatocytes, 8 in 1/3 to 2/3 of hepatocytes, 3 in less than 1/3 and 3 were not steatotic. Fifteen HCA had no mutations in HNF1α, four of them were β-catenin mutated, five were inflammatory and 9 demonstrated steatosis. Nontumor liver tissues were taken from patients resected with primary liver tumors developed in the absence of cirrhosis. Steatotic non-tumor livers demonstrated lipid storage either in more than 2/3 of hepatocytes (four cases) or in 1/3 to 2/3 of hepatocytes (7 cases), and were of various etiologies: HCV (one case), dysmetabolic syndrome (6 cases), alcohol (three cases), and unknown etiology (one case).
Microarray analysis. Total RNA was extracted from frozen tissues using Qiagen RNeasy kits (Qiagen) according to the manufacturer's instructions. RNA integrity was assessed using RNA 6000 nano chips and the Agilent 2100
Bioanalyzer. RNA quality control was performed as previously described (6) . Transcriptional profiling of HNF1α-mutated HCA and nontumor liver tissues was performed using two different microarray approches. MIAMEcompliant data (7) have been deposited in Gene Expression Omnibus (GEO) at NCBI (http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series accession number GSExxxx and GSExxxx. Detailed procedure of analysis is provided in the supplemental experimental procedures.
Quantitative RT-PCR. Quantitative RT-PCR was performed as previously described (8) using predesigned primers and probe sets from Applied Biosystems for the detection of R18S, FABP1, PCK1, PCK2, FBP1, G6PT1, GCK, GCKR, GPI, ME1, MDH1, ACLY, PKLR, PKM2 (detection of both PKM1 and PKM2 transcripts), ACACA, FASN, ELOVL1, ELOVL2, ELOVL5, SCD, FADS1, FADS2, SREBP-1 (detection of both SREBP-1a and SREBP-1c isoforms), SREBP-1a, CHREBP, PPARα, PPARγ, LXRα and HNF4α. Ribosomal 18S (R18S) was used for the normalization of expression data. The relative amount of measured mRNA in samples, was determined using the 2 -∆∆CT method where ∆∆CT = (CT target -CT R18S ) sample -(CT target -CT R18S ) calibrator . Final results were expressed as the n-fold differences in target gene expression in tested samples compared to the mean expression value of non-tumor tissues.
Western blotting. Total protein extracts were obtained after homogenization in RIPA lysis buffer (Santa Cruz Biotechnology). Nuclear extracts were prepared using the NE-PER nuclear and cytoplasmic extraction reagent kit (Pierce) and protein concentration was determined using a Pierce BCA protein assay kit. Primary antibodies were used at the following dilutions: rabbit polyclonal anti-L-FABP 1:2000 (a gift of Dr. J Gordon), mouse monoclonals anti-FAS and anti-SREBP-1 (detecting both the SREBP-1a and SREBP-1c isoforms) 1:500 (BD Bioscience Pharmingen), polyclonals rabbit anti-GK (Santa Cruz Biotechnology) and anti-ACL (Cell Signaling Technology) 1:200, polyclonal rabbit anti-ChREBP 1:1000 (Novus Biologicals). We used polyclonal rabbit anti-actin (1:3000, Sigma) and polyclonal rabbit anti-Lamin A/C (1:500, Cell Signaling Technology) as loading controls to normalize the signal obtained respectively for total and nuclear protein extracts. Detection of signals was performed using the ECL SuperSignal West Pico Chemiluminescent Substrate (Pierce) with either anti-mouse (1:4000, Amersham) or anti-rabbit (1:2000, Santa Cruz Biotechnology) horseradish peroxidase-conjugated IgG as second antibodies.
Glucose-6-phosphate measurement. Glucose-6phosphate (G6P) concentrations were determined enzymatically in normal and tumor samples by exploiting the selective and quantitative conversion of G6P to 6-phosphogluconic acid in presence of NADP + and G6PDH, as previously described (9) .
Histochemical analysis of glycogen storage. For this analysis, we used liver tissues frozen through immersion in isopentane cooled in liquid nitrogen. PAS histochemical staining was performed on frozen section from 5 HNF1αmutated HCA and 5 non-mutated HCA as well as their matched non-tumor livers.
Lipid profiling. Detailed protocols used for lipid profiling are provided in the supplemental experimental procedures.
Statistical analysis. All the values reported are mean ± SD. Statistical analysis was performed using GraphPad Prism version 4 software and significance was determined using the nonparametric Mann-Whitney test for unpaired data. Difference was considered significant at P<0.05.
RESULTS
Gene expression profiles in HNF1α-mutated HCA. Our cDNA and Affymetrix microarray experiments analyzed the expression of a total of 15,000 different genes comparing respectively 8 HNF1α-mutated HCA to their corresponding non-tumor liver and five HNF1α-mutated HCA to four non-tumor livers. Computational analysis of both experiments identified 375 and 222 genes respectively significantly down and upregulated in HNF1α-mutated HCA. Among these genes, a large fraction was related to the normal hepatocyte function including carbohydrate and lipid metabolism, detoxification and synthesis of secreted proteins such as complement and coagulation factors (Supplemental Table 1 ). Among differentially expressed genes, promoter regions of 33 were previously identified to bound HNF1α in primary human hepatocytes using ChIP-on-chip technology (10) . All but four of theses genes were downregulated in HNF1α-mutated HCA (Supplemental Table 1 ), which is in accordance with the well-known transactivating function of HNF1α. In addition, we identified 82 genes showing a common pattern of expression with liver from hnf1α-null mice (11) (Supplemental Table 1 ). Interestingly, 19 of these common deregulated genes were involved in glucidolipidic metabolism and particularly in bile acid metabolism, cholesterol and fatty acid synthesis (Supplemental Table 1 ).
Fatty acid transport and oxidation. In HNF1αmutated HCA, we identified an important modification in the expression profiles of apolipoprotein genes. Particularly, components of the HDL particles encoded by APOM, LPAL2, APOF, LPA and APOA4 were strongly downregulated while APOL3 was upregulated (Supplemental Table 1 ). In contrast, the expression of critical genes for hepatocyte VLDL assembly and secretion such as APOB and MTP was not affected. We also found a dramatic decrease in the mRNA of FABP1 encoding the liver fatty acid binding protein (L-FABP). This result was confirmed by quantitative RT-PCR (-68-fold change, Figure  1A ) and by western-blotting analysis that showed an absence of L-FABP in mutated HCA ( Figure 1B) . In contrast, we did not find any change in the expression of genes encoding mitochondrial and peroxisomal β-oxidation enzymes. The expression level of genes encoding plasma membrane transporters such as CD36 was also normal in mutated HCA as well as the LDL receptor gene. However, we identified a number of deregulated genes related to the lipogenesis pathway (Figures 2A and 3A) .
Gluconeogenesis repression and glycolysis
activation. The expression of four genes (FBP1 encoding the fructose-1,6-bisphosphatase, PCK1 and PCK2 encoding respectively the cytosolic and the mitochondrial forms of the PEPCK enzyme and G6PT1 encoding the glucose-6phosphate transporter 1) critical to promote hepatic glucose production was significantly decreased in HNF1α-mutated HCA ( Figure 2B ), indicating a repression of the gluconeogenesis pathway in these tumors (Figure 2A ). In contrast, glycolysis was activated in HNF1α-mutated HCA, since we found a strong upregulation of glucokinase at the mRNA (GCK, 11-fold) and protein level (GK, Figure 2B and 2C). In addition, we found a 3-fold decrease in the expression of the GCKR transcript whose product acts as a negative regulator of glucokinase ( Figure 2B ). According to a predicted increased glucose phosphorylation rate, we showed a significantly higher level of glucose-6-phosphate in HNF1α-mutated HCA ( Figure 2D ). Moreover, PAS staining revealed a glycogen overload in these tumors consistent with G6P increase ( Figure 2E ). We also found an upregulation of GPI mRNA (4-fold, Figure 2B ) which encodes the glucose phosphate isomerase, a second glycolytic enzyme. In contrast, PKLR mRNA which encodes the liver specific pyruvate kinase that catalyzes the last irreversible step of glycolysis was 3-fold decreased in HNF1αmutated HCA ( Figure 2F ). However, PKLR downregulation may be balanced by a 2-fold increase of PKM2 gene that encodes the muscle specific pyruvate kinase ( Figure 2F ).
Activation of the citrate shuttle. Besides the observed gluconeogenesis inhibition and glycolysis
activation that predict an overproduction of pyruvate, a substrate for the mitochondrial synthesis of acetylCoA, the citrate shuttle system that export acetylCoA into the cytosol was also activated in HNF1α-mutated HCA (Figure 2A ). Indeed, we found a 12-fold overexpression of ME1 mRNA which encodes the malic enzyme, a moderate 2-fold increase of MDH1 transcript and ACLY mRNA encoding the ATP citrate lyase (ACL) was 3.7-fold overexpressed in HNF1α-mutated HCA ( Figure  2B ). As ATP citrate lyase is crucial to provide the unique cytoplasmic source of the acetylCoA lipogenic precursor, we confirmed by westernblotting the ACL protein overexpression ( Figure  2C ).
Stimulation of the fatty acid synthetic pathway.
As shown in Figure 3A , the fatty acid synthetic pathway was also stimulated in HNF1α-mutated HCA. We found an increase of the acetyl-CoA carboxylase transcript (ACACA, 2.6-fold) and a strong overexpression of fatty acid synthase at both trancriptional (FASN, 7-fold) and protein level (FAS, Figures 3B and 3C ). In the downstream steps of fatty acid elongation and desaturation, we also identified an increase in the mRNA level of three genes encoding elongases including ELOVL1 (3.4-fold), ELOVL2 (2.2fold) and ELOVL5 (2.3-fold) and of three genes encoding desaturases such as SCD (6-fold), FADS1 (3-fold) and FADS2 (4.7-fold, Figure  3B ).
Transcriptional alteration of glucido-lipidic genes defines an expression pattern that is specific of HNF1α-mutated HCA. To search if the pattern of alteration in the expression of the glucido-lipidic genes was specific of HNF1α inactivation, we compared the expression profiles of the 19 aforementioned genes between HNF1α-mutated HCA and a group of nonmutated HCA containing or not steatosis, using quantitative RT-PCR. In this analysis, we also included steatotic non-tumor livers from different etiologies and non steatotic non-tumor livers. We then performed a non-supervised analysis of the results using a hierarchical clustering algorithm to group the genes as well as the samples on the basis of similarity in their expression pattern. This analysis accurately classified all samples in two major clusters according to their HNF1α status ( Figure 4 ). Steatotic non-tumor livers and non-steatotic nontumor livers were gathered with the non-HNF1αmutated HCA. Gene cluster analysis identified two main groups corresponding to downregulated (cluster A) and upregulated (cluster B) genes in HNF1α-mutated HCA ( Figure 4 ). As expected, four out of five genes identified in cluster A had been previously characterized as HNF1α transactivated targets. Interestingly, all upregulated genes have never been previously found regulated by HNF1α. Within cluster B, three subgroups of genes (1, 2, 3) showed a highly correlated overexpression in HNF1α-mutated HCA (Supplemental Figure 1 ). For example, ACLY level of expression was correlated to ACACA overexpression in 16 HNF1α-mutated HCA (Spearman r=0.72, P=0.001) (Supplemental Figure 1) . In non-HNF1α-mutated liver tissues, only few genes demonstrated a significant transcriptional deregulation (Supplemental Figure 2 ). In steatotic non-tumor livers, expression of only two genes, PCK2 and ME1, followed an expression pattern as seen in HNF1α-mutated HCA (Supplemental Figure 2 ). In non-HNF1αmutated steatotic HCA, 9 genes involved in gluconeogenesis, glycolysis and citrate shuttle were significantly deregulated compared to the non-steatotic non-tumor livers (Supplemental Figure 2 ). One of these, GCK, showed an inversed pattern of deregulation when compared to the HNF1α-mutated HCA. However, except a modest elevation in ELOVL1 transcript, expression of genes related to the fatty acid synthetic pathway were unchanged in this group of steatotic adenomas. Finally, in the group of non-HNF1α-mutated non-steatotic HCA only four genes showed a significant change in expression pattern (FBP1, GPI, ACLY, ELOVL1). These results indicated that patterns of expression of the 19 analyzed genes were specific to HNF1α inactivation. Downregulations could be directly attributed to the loss of the classical HNF1α transactivation activity. In contrast, overexpressed genes demonstrated a coordinated activation, but none are known to date to be directly controlled by HNF1α.
Activation of lipogenesis in HNF1α-mutated
HCA is independent of SREBP-1 and ChREBP activation. Among the lipogenic genes whose expression was increased in HNF1α-mutated HCA, 8 out of 13 were previously described as SREBP-1c targets. However, using quantitative RT-PCR, we did not find any significant variation in the mRNA level of total SREBP-1 in HNF1α-mutated HCA compared to non-tumor livers, nor in SREBP-1a ( Figure 6A ). Moreover, surprisingly, western-blotting studies revealed a decrease in the nuclear active form of SREBP-1 in the tumors compared to their corresponding non-tumor liver ( Figure 6B ), and the microarray study also found an increase in INSIG1 (insulin induced gene 1) mRNA (2 fold, Supplemental Table 1 ) whose product is known to inhibit SREBP-1 cleavage processing. We then looked for a potential alteration of ChREBP expression, an other key transcriptional activator of fatty acid synthesis in the liver. RT-PCR results showed a significant decrease in the mRNA of CHREBP in HNF1α-mutated HCA (-1.8-fold, Figure 6A ) and western blotting studies revealed a decrease of the protein level in the nucleus ( Figure 6B ). Using the same samples where we demonstrated a repression of both SREBP-1 and ChREBP, we found an obvious overexpression of the fatty acid synthase (FAS) and glucokinase (GK) proteins, which are known to be transactivated by these two transcription factors ( Figure 6B ). Although unexpected, these results suggest that increased lipogenic genes expression found in HNF1α-mutated HCA is not related to SREBP-1 and ChREBP activation. FAS and GK overexpression were confirmed in three additional cases of HNF1α-mutated HCA (Supplemental Figure 3 ). In two of these three cases, ChREBP was decreased and the nuclear active form of SREBP-1 was highly reduced or unchanged. In the remaining case we found a mild elevation of ChREBP and nuclear SREBP-1 compared to the non-tumoral counterpart. On the whole, we observed an increased expression of FAS and GK together with a clear repression of SREBP-1 and ChREBP in four out of 6 HNF1αmutated HCA analyzed. Interestingly, no similar pattern of expression was found in the non-HNF1α-mutated HCA tested (Supplemental Figure 3 ). We also checked for the transcriptional level of other transcription factors that have been implicated in the regulation of glucido-lipidic metabolism ( Figure 6A ). Except for a 1.9-fold elevation of PPARγ transcript, the mRNA level of FOXO1A, PPARα, LXRα and HNF4α was not significantly different in HNF1α-mutated HCA compared to non-tumor livers ( Figure 6A ). Finally, the RXR isotypes genes were not differentially expressed in the microarray analysis.
Total lipid composition is modified in HNF1αmutated HCA. We compared lipid profiles of four non-steatotic non-tumor livers with that of five HNF1α-mutated HCA. Total fatty acid content was 5.8-fold increased in HNF1αmutated HCA and the fatty acid profile was modified. Saturated (SFA) and monounsaturated (MUFA) fatty acids were 7-and 8-fold increased respectively, as a consequence of the accumulation of all SFA and MUFA species detected ( Figure 3A , 5C and 5D). In contrast, polyunsaturated fatty acids (PUFA) were raised only 2-fold ( Figure 5A ) with a preferential accumulation of fatty acids containing 18 carbon atoms including the two essential fatty acids linoleic acid (18:2n-6) and α-linolenic acid (18:3n-3). Consequently, the SFA/PUFA and MUFA/PUFA ratios in mutated HCA were significantly higher than in non-tumor livers ( Figure 5B ). We also showed that C14-C18 fatty acids were much more increased than C20-C23 fatty acids, as indicated by a 5-fold higher C14-C18/C20-C23 ratio ( Figure 5B ). We also identified a mild elevation in free cholesterol content in HNF1α-mutated HCA (36 vs 26.2 nmol/mg of proteins, Figure 5F ), however, we did not find any change neither in total cholesterol esters and diglycerides contents ( Figure 5F ) nor in specific molecular species related to these two neutral lipid classes (data not shown). In contrast, total and all species of triglycerides were dramatically increased in HNF1α-mutated HCA ( Figures 5F and 5G ). This overload was inversely proportional to the total number of carbon atoms of each species (ranging from a 53-fold for C49 to a 4.8-fold increase for C57 families, Figure 5G ), according to the highest increase in C14-C16 fatty acid species versus C18-C20.
Phospholipid profile is also changed in HNF1αmutated HCA. As shown in Table 1 , HNF1αmutated HCA showed a 2-fold increase in total phospholipid quantity that was related to a significant elevation of phosphatidylcholine (PC) and phosphatidylethanolamine (PE), while content of the other phospholipid classes including sphingomyelin (SM) was unchanged compared to non-tumor livers (except for PS that was undetectable in the tumors). Our results also showed a significant elevation in the PE fraction whereas the PI fraction was reduced ( Table 1) , indicating that phospholipid profile was qualitatively changed. The fatty acid profile of PE was not significantly modified, while it was moderately alterated for PC and PS-PI classes ( Table 2 ). In PS-PI, we found a significant elevation of the MUFA fraction ( Table 2 ). In PC, the SFA and PUFA fractions were respectively decreased and increased, consequently, the PCunsaturation index was significantly increased in HNF1α-mutated HCA ( Table 2 ). We also showed that C20-C24 were over-represented in the PC fraction of HNF1α-mutated HCA, as indicated by the significant decrease of the C16-C18/C20-C24 ratio (1.8 fold). When analyzing fatty acid composition of the total phospholipids, we only found a reduction in the C16-C18/C20-C24 ratio in HNF1α-mutated HCA ( Table 2 ).
DISCUSSION
In the present work, careful analysis of the metabolic pathways alterated in the HNF1αmutated HCA may explain the severe fatty overload observed in these tumors. First, we identified a repression of gluconeogenesis coordinated with an activation of glycolysis and citrate shuttle predicting an aberrant accumulation of the acetylCoA and NADPH lipogenic precursors (12) . In addition, these tumors also showed an obvious stimulation of the fatty acid synthetic pathway from palmitate synthesis to the downstream steps of fatty acid elongation and desaturation. Taken together, these findings provide evidence that de novo lipogenesis activity is increased in HNF1αmutated HCA, and we showed that it is specifically related to the loss of HNF1α activity. The fact that the steatotic non-HNF1αmutated HCA and the steatotic non-tumor livers did not show the same deregulated expression pattern as in mutated HCA suggests that lipid storage in these two groups of samples likely occurs independently of HNF1α inactivation. Moreover, since lipogenesis activity is known to be mainly regulated at the transcriptional level, it is unlikely that higher lipogenic rates would be a significant driver of fat accumulation in the steatotic non-HNF1α-mutated HCA or in the steatotic non-tumor livers. Indeed, in these two sample groups, no major transcriptional deregulation was found in the lipogenic pathway. However, it does not exclude a possible activation of lipogenesis at a post-transcriptional level. The importance of lipogenesis in human steatosis is still under discussion. Here, we report a particular situation in humans, in which hepatocyte steatosis developed in the context of HNF1α inactivation seems to be primarily due to an aberrant stimulation of lipogenic rate.
In mice, loss of HNF1α activity was also associated with the development of fatty liver (13, 14) , and a prior work identified a significant elevation in the liver expression of the acetyl-CoA carboxylase and fatty acid synthase genes (14) . However, our study is the first one to demonstrate a coordinate overexpression of all lipogenic genes and to highlight the major involvement of this aberrant induction in the pathogenesis of fatty liver phenotype related to HNF1α inactivation. In the present work, we identified transcriptional deregulations of 19 genes that may explain fat overload observed in the human HNF1α-mutated HCA. Interestingly, when extracting the expression data from the transciptome analysis performed by Shih et al. in the liver from hnf1α-null mice, we found that 9 of theses 19 genes were commonly deregulated in mice. Moreover, it is remarkable that the most important overlap was found for the genes involved in the fatty acid synthetic pathway (5/9).
Among the 19 deregulated genes, three of the 6 downregulated genes (FABP1, G6PT1 and PCK1) were previously demonstrated to be directly transactivated by HNF1α and promoter region of GCKR has been shown to bind HNF1α in vivo by ChIP (10, (14) (15) (16) . However, among the overexpressed genes, the majority were known to be transactivated by the membrane bound transcription factor SREBP-1c. SREBP-1c is considered as the master regulator of fatty acid synthesis in the liver, mediating effects of insulin on the expression of glycolytic and lipogenic genes after being activated by proteolytic cleavage (17) . Surprisingly, in HNF1α-mutated HCA, SREBP-1 was repressed in most of the cases, possibly resulting from the induction of INSIG1 mRNA (18) . This finding contrasts with that found in hnf1α-null mice liver in which a significant increase of SREBP-1 transcript was reported (11) . ChREBP is an other transcription factor known to activate the expression of some lipogenic genes such as ACLY, ACACA, FASN (19) . In HNF1α-mutated HCA we also found a reduction of the ChREBP mRNA level and nuclear protein amounts, demonstrating repression. This could occur as a consequence of the observed PUFA elevation in the tumors and particularly of the linoleic acid, that has been shown to suppress ChREBP activity by increasing its mRNA decay and altering its translocation from the cytosol to the nucleus (20) . Thus, the repression of SREBP-1 and ChREBP observed in most of the analyzed HNF1α-mutated HCA could result from a negative feedback responding to lipid overload. Furthermore, although a large fraction of SREBP-1 targets were overexpressed in HNF1αmutated HCA, some well-known targets such as the 6-phosphogluconate dehydrogenase (6PGDH) and glucose-6-phosphate dehydrogenase (G6PDH), were not deregulated in mutated HCA. Altogether, our results imply that SREBP-1 and ChREBP are not responsible for the coordinate induction of glycolytic and lipogenic genes observed in HNF1α-mutated HCA. PPARγ was previously proposed to play a role in hepatic induction of lipogenic genes through a mechanism that is still unclear (21) (22) (23) . In the HNF1α-mutated HCA, we found an increase in PPARγ gene expression, however, among three well-known targets of this transcription factor (FABP4, CD36 and UCP2) only one demonstrated a significant overexpression (FABP4 gene 5-fold, Supplemental Table 1 ) suggesting that PPARγ activity is not obviously increased in HNF1αmutated HCA. Thus, the mechanism by which HNF1α inactivation leads to the coordinate overexpression of the lipogenic genes remains to be elucidated. The strong correlation groups identified between overexpressed transcripts suggest that a transcriptional mechanism would be most likely at the origin of the observed deregulations, instead of a post-transcriptional regulation such as mRNA stability. Consequently, transcriptional activation of the lipogenic genes related to HNF1α inactivation may occur through the loss of a direct HNF1α repressor function involving either direct DNA binding or interaction with others transcription factors and co-activator proteins (Supplemental Figure 4A ). Although, HNF1α has been mainly reported as a transcriptional activator, this model would explain some of the identified overexpressions. Indeed a co-repressor activity for HNF1α on its own transcription has already been shown through interaction with HNF4α (24). Alternatively, the absence of a functional HNF1α protein may also alter the expression of another transcription factor involved in the control of lipogenesis (Supplemental Figure 4B ). New insights into understanding the mechanisms regulating lipogenic gene expression by HNF1α could come from the analysis of gene promoter activity in cellular systems in which HNF1α activity will be modulated.
Results from lipid profiling analysis of the accumulated fat in HNF1α-mutated HCA are well correlated with the transcriptional deregulations observed in the fatty acid synthetic pathway. Indeed, the preferential accumulation of SFA and MUFA species is in accordance with the strong overexpression of FAS and SCD, and with the high elevation of ELOVL1 expression (25) (26) (27) . The significant accumulation of the two essential fatty acids linoleic acid and α-linolenic acid suggests that in addition to the elevated rates of lipogenesis, other mechanisms may contribute to the fatty phenotype in HNF1αmutated HCA. This is unlikely the consequence of impaired VLDL secretion or fatty acid entry into the tumor hepatocytes, since no obvious deregulations in the expression of the genes involved in these processes was identified. However, although expression of fatty acid oxidation genes was unchanged in HNF1αmutated HCA, it is likely that fatty acid oxidation is reduced in adenoma cells secondary to lipogenic rate increase. Indeed, this may occur through the inhibition of CPT1 activity resulting from the overproduction of malonyl-CoA by the acetylCoA carboxylase whose transcript was significantly upregulated in HNF1α-mutated HCA. Thus, a secondary defect in β-oxidation may contribute to fat accumulation and may explain in part the observed elevation of essential fatty acids. Moreover, given the role of L-FABP in binding, trafficking and compartmentalization of fatty acids into the hepatocyte, the dramatic decrease in L-FABP expression may also participate to the steatotic phenotype, as suggested in hnf1α-null mice liver (28) . The alteration of phospholipid profile in HNF1αmutated HCA was moderate. However, it may cause deregulation of membrane functioning in adenoma cells leading to alteration of critical cellular processes related to tumorigenesis.
In this study, we clearly demonstrated that lipogenesis activity was increased in HNF1α-mutated HCA and this feature has been commonly observed in tumor cells. Indeed, overexpression of the fatty acid synthase was previously identified in a wide variety of cancers as well as in precancerous lesions (29) . This overexpression was often accompanied by a coordinate induction of the other lipogenic enzymes and several studies have shown that tumor cell survival may depend on de novo synthesis of fatty acids. While the fatty acid synthase as been proposed as an interesting therapeutic target for cancer treatment, more recent studies showed that the inhibition of other lipogenic enzymes like acetylCoA carboxylase or ATP citrate lyase can also limit cancer cell proliferation and survival (30, 31) . Recently, we proposed HNF1α as a tumor suppressor gene (3) and we demonstrated in the present work, that lipogenesis activation in HNF1α-mutated HCA results from the loss of HNF1α activity. This finding may contribute to reinforce the emerging concept that induction of lipogenesis observed in tumor cells would occur downstream from oncogenic events (29) and open new avenues to understand how metabolism deregulations may contribute to benign liver tumorigenesis. Finally, our findings have potential clinical implications since lipogenesis can be efficiently inhibited by targeted therapies.
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SUPPLEMENTAL DATA

Supplemental experimental procedures
Microarray analysis. In a first experiment, expression patterns were compared between 8 HNF1αmutated HCA and their corresponding non-tumor livers using cDNA in-house manufactured arrays previously described (1) . Briefly, one microgram of each amplified RNA and human universal reference RNA (Stratagene) were labeled alternatively with Cy5-dCTP and Cy3-dCTP and cohybridized onto glass array slides containing 11,250 cDNA spotted sequences. We carried out two hybridizations for each tissue using a dye-swap strategy. Primary data collection, filtering and normalization of gene expression were done as described in Graudens et al, (1) .
In the second experiment, we used HG-U133A Affymetrix GeneChip TM arrays to compare the expression profiles of 5 HNF1α-mutated HCA and 4 non-related non-tumor livers analysing the expression level of 19,787 probe sets.
Statistical analysis of both cDNA and Affymetrix GeneChip arrays data was performed using multiple testing procedures to evaluate statistical significance for differentially expressed genes, as previously described (1) . Two gene selection methods were applied (i) significance analysis of microarrays [SAM; (2) ], and (ii) p-value ranking using z-statistics in ArrayStat 1.0 software (Imaging Research Inc.), t-statistics via the dChip program and the class comparison tools available in BRB-ArrayTools v3.2.3 package, an Excel Add-in (3). Statistical tests were computed for each probe set using the log-transformed data and a probe set was declared to be significant when the p-value was less than the α-level=0.001. For multiple testing corrections, the false discovery rate (FDR) procedure was used (4). Univariate and multivariate permutation tests (n>1000) were computed to control the proportion of false discoveries (i.e. false positives, > 90% confidence) in the "discovery list". To assess the classification accuracy, a variety of methods were used in BRB-ArrayTools v3.2.3 package, including unsupervised compound covariate, diagonal linear discriminant analysis, k-nearest-neighbor (k=1 and 3), nearest centroid, and support vector machine predictors. For all of those class prediction methods, the cross-validated misclassification rate was calculated using the leave-one-out voting classifier validation (α-level=0.001).
Lipid profiling. Following homogenization of tissue samples in methanol/ 5mM EGTA (2:1 v/v), lipids corresponding to an equivalent of 1 mg of tissue were extracted according to Bligh and Dyer (5) in chloroform/methanol/water (2.5 :2.5 :2.1, v/v/v), in the presence of the internal standards : 6 μg of stigmasterol, 4 μg of 1,3-dimyristine, 4 μg of cholesteryl heptadecanoate and 6 μg of glyceryl triheptadecanoate. Neutral lipids were analyzed by gas-liquid chromatography on a FOCUS Thermo Electron system using a Zebron-1 Phenomenex fused silica capillary columns (5m X 0,32mm i.d, 0.50 mm film thickness) (6) . Oven temperature was programmed from 200°C to 350°C at a rate of 5°C per min and the carrier gas was hydrogen (0.5 bar). The injector and the detector were at 315°C and 345°C respectively.
To measure total fatty acid methyl ester molecular species (FAME), lipids corresponding to an equivalent of 1mg of liver were extracted in the presence of glyceryl triheptadecanoate (0.5μg) as an internal standard. The lipid extract was transmethylated with 1ml of acetyl chloride in methanol (1 /20, v/v) for 90 min at 55°C, evaporated to dryness and the FAMEs were extracted with hexane/water 1:1. The organic phase was evaporated to dryness and dissolved in 50μl ethyl acetate. 1μl of FAME was analyzed by gas-liquid chromatography (7) on a 5890 Hewlett Packard system using a Famewax RESTEK fused silica capillary columns (30 m x 0.32 mm i.d, 0.25 mm film thickness). Oven temperature was programmed from 110°C to 220°C at a rate of 2°C per min and the carrier gas was hydrogen (0.5 bar). The injector and the detector were at 225°C and 245°C respectively.
Measurement of fatty acid methyl ester molecular species of phospholipids was performed using lipid extract corresponding to an equivalent of 5 mg of liver. Phospholipids were separated by Thin Layer Chromatography in chloroform:methanol:water:acetic acid (65:43:3:1). Standards were run in parallel, stained with iodine and phospholipids spots were identified, scrapped and eluted three times with 1ml of chloroform:methanol (2:1). Extracts from PC, PS-PI and PE were evaporated to dryness and transmethylated in the presence of nonadecanoic acid (2 μg). FAMEs were extracted in hexane, re-dissolved in 20μl of ethyl acetate and analysed as above.
To measure phospholipid classes, lipids corresponding to an equivalent of 2 mg of liver were extracted. The lipid extract was dissolved in 40 μl of chloroform and 20μl was analysed by HPLC on a Summit DIONEX system using a Uptisphere 6OH (5μm) 250 X 2mm column. The flow rate was 0.2 ml/min and the column temperature was kept at 35°C during all runs. A light-scattering detector was used for the detection (Polymer Laboratories PL-ELS2100). The evaporator and nebulisator temperature was 80°C, and nitrogen pressure was 1.2 ml/min. A ternary solvent system was used: A, isopropanol; B, hexane; C, water. Triethylamine (0.08%, v/v) and acetic acid (1%, v/v) were added to the solvents. The column was equilibrated in 60% B and 2% C and the sample was injected Then the gradient was moved to 49% B and 5,6% C in 23 min and to 0% B and 14% C in 7 min. Finally the gradient was returned to the starting conditions in 10 min and the column was equilibrated for 45min before next run. Supplemental Fig 1. Correlations between overexpressed transcripts of the lipogenesis pathway identified in HNF1α-mutated HCA. A. Correlations for each upregulated transcript versus the other indicated upregulated transcripts were assessed by Spearman's rank correlation test using the quantitative RT-PCR data obtained in the group of HNF1α-mutated HCA. *, **, *** difference between groups at P<0.05, 0.01, and 0.001 respectively (significant correlations are highlighted in black). ns: correlation is not significant. B. Example of graphical representation of significant correlations identified between FASN, ACLY and ACACA transcripts, three key genes of the lipogenesis pathway.
Supplemental Tables and Figures
Supplemental Fig 2. Expression of the 19 differentially expressed genes that may explain steatosis in HNF1α-mutated HCA, in other subtypes of liver tissues with or without steatosis.
mRNA level was assessed using quantitative RT-PCR. For each group of samples, results are expressed as the n-fold difference in gene expression relative to the mean expression value of nonsteatotic non-tumor livers. Data are mean ± SD. *, **, *** difference between groups at P<0.05, 0.01, and 0.001 respectively.
Supplemental Fig 3. Expression of SREBP-1, ChREBP, FAS and GK proteins in
HNF1α-mutated HCA and in non-HNF1α-mutated non-steatotic HCA. SREBP-1 (precursor form 125 kDa and mature form 68 kDa) and ChREBP (95 kDa) expression was analyzed by westernblotting in total and nuclear protein fraction from three additional cases of HNF1α-mutated HCA (T 4 , T 5 , T 6 ) and their respective corresponding non-tumor liver (N 4 , N 5 , N 6 ), as well as in three non-HNF1α-mutated non-steatotic HCA (T 7 , T 8 , T 9 ) and their respective corresponding non-tumor liver (N 7 , N 8 , N 9 ). The expression level of FAS (265 kDa) and GK (52 kDa) proteins, two targets of SREBP-1 and ChREBP was also assessed in the total protein fraction from the same samples. β-actin and Lamin A/C were used as loading controls for total and nuclear extracts respectively.
Supplemental Fig 4. Model of the hypothetical mechanisms by which HNF1α may control lipogenic gene expression.
A. Direct mechanism: HNF1α may act as a direct repressor of lipogenic genes promoter activity, through direct DNA binding or by interacting with an unknown activator transcription factor or co-activator proteins (A). B. Indirect mechanism: 1) HNF1α may activate the transcription of a repressor protein (R) involved in the promoter repression of lipogenic genes 2) HNF1α may repress the expression of an activator protein (A) involved in the transcriptional activation of the lipogenic genes expression. Supplemental Table 1 
Fold change T/N Genes commonly
. Results from cDNA and Affymetrix microarray experiments comparing respectively 8 HNF1αmutated HCA to their matched non-tumor livers (N), and five HNF1α-mutated HCA to four non-related non-tumor livers.
Data are expressed as the n-fold difference in gene expression in HNF1 α-mutated HCA (T) relative to non-tumor livers (N). Genes commonly deregulated in hnf1 α -null mice (+) includes primarily data extracted from the transcriptional profiling analysis performed by Shih et al. in the liver from hnf1 α -null mice and others previous candidate gene approach studies, red and green colors indicate respectively genes whose expression was found upregulated and downregulated in the liver from hnf1 α -null mice.
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